RxDoctor Payments Data

Vasanth Bethala, MD

Interventional Cardiology · Slidell, LANPI 1548263999

Payments from drug & device makers

$11,479in general payments, 2019–2025

Across 379 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Edwards Lifesciences$691
  • Abiomed$625
  • Johnson & Johnson$608
  • Pfizer$534
  • E.r. Squibb & Sons, L.L.C.$466
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$2,85925%
  • Food & beverage$8,62075%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,479 in reported general payments places this provider in the 50th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$197,698
Medicare patients
1,987
Services billed
4,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban439$488,644
EntrestoSacubitril/Valsartan166$192,306
XareltoRivaroxaban121$129,714
MultaqDronedarone Hcl58$62,249
JardianceEmpagliflozin50$44,484
Repatha SureclickEvolocumab46$32,055
Ranolazine ErRanolazine276$20,977
NexletolBempedoic Acid18$14,613
BrilintaTicagrelor16$9,591
Metoprolol Succinate627$8,822
Rosuvastatin Calcium551$7,344
Praluent PenAlirocumab12$6,086
Ezetimibe268$5,819
Losartan Potassium486$5,645
Isosorbide Mononitrate ErIsosorbide Mononitrate285$4,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$534$488,644439 claims
NovartisEntresto$314$192,306166 claims
Johnson & JohnsonXarelto$608$129,714121 claims
Sanofi-aventis U.S. LLCMultaq$220$62,24958 claims
Boehringer IngelheimJardiance$118$44,48450 claims
Esperion Therapeutics, Inc.Nexletol$233$14,61318 claims
AstraZenecaBrilinta$78$9,59116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →